Vascular Biogenics Ltd. VBLT

Full chart Compare
Set alert

Price alert · VBLT

All alert types
0.16 0.00 (+0.00%)

At closeOct 16, 2023, 4:00 PM EDT

0.1526 Day range 0.1925

52-week range unavailable

Market cap
12.11M
Revenue (ttm)
481.00K
Shares out
77.64M
Forward P/E
-0.26
Volume
5.38M
Open
0.1734
Previous close
0.156
Day's range
0.1526 – 0.1925
Beta
0.71
Analysts
Hold
Earnings date
Nov 13, 2023

 

No chart data for this range yet.

Key statistics

Enterprise value
-10.99M
PEG ratio
0.00
Price / sales
25.18
Price / book
0.57
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-10.84M
Total cash
24.26M
Total debt
0
Return on equity
-59.52%
Short % of float
0.33%
50-day average
0.228423
200-day average
0.206284

Financials — quick view

All financials
VBLT Revenue — quarterly 0
2019-09-302019-12-312020-03-312020-06-302020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-30
VBLT Net income — quarterly -874.00K
2019-09-302019-12-312020-03-312020-06-302020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-30
VBLT EPS — quarterly 0.01
2019-09-302019-12-312020-03-312020-06-302020-09-302020-12-312021-03-312021-06-302021-09-302021-12-312022-03-312022-06-302022-09-302022-12-312023-03-312023-06-30

Earnings

VBLT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2023Sep 1, 20230.00———
Aug 14, 2023Jun 1, 20230.00———
May 15, 2023Mar 1, 20230.00———
Mar 14, 2023Dec 1, 20220.00———
Nov 14, 2022Sep 1, 2022-0.11———
Aug 15, 2022Jun 1, 2022-0.13———

Upgrades / downgrades

VBLT analyst upgrades and downgrades
DateFirmActionFromTo
Jul 20, 2022Chardan CapitaldownBuyNeutral
Jul 19, 2022HC Wainwright & Co.downBuyNeutral
Apr 27, 2022Chardan Capitalinit—Buy
Jun 2, 2021Roth Capitalmain—Buy
Jan 27, 2021HC Wainwright & Co.main—Buy
Apr 16, 2020Oppenheimermain—Outperform

About Vascular Biogenics Ltd.

Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Sector
Healthcare
Industry
Biotechnology
Country
Israel
Website
vblrx.com

News

Your note

Sign in to keep a note on VBLT — it syncs with the Stock Master app.

Insider holders

VBLT insider holders
InsiderRelationLatest transactionDateShares held
BACKENROTH SAMUELChief Financial OfficerConversion of Exercise of derivative securityMar 30, 2023525,000

Institution ownership

VBLT institution ownership
Holder% heldSharesValueReported
Telemetry Investments, L.L.C.0.57%403,50048.42KDec 30, 2022
Morgan Stanley0.46%327,01175.21KJun 29, 2023
Group One Trading, L.P.0.18%127,29329.28KJun 29, 2023
Virtu Financial LLC0.11%79,89218.38KJun 29, 2023
Catalyst Financial Partners LLC0.06%39,0008.97KJun 29, 2023
Geode Capital Management, LLC0.06%40,3239.27KJun 29, 2023

Fund ownership

VBLT fund ownership
Holder% heldSharesValueReported
Fidelity NASDAQ Composite Index Fund0.06%40,3238.46KMay 30, 2023